FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 589 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... March 23, 2022 Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... July 3, 2024 Puppy That Was Born Dead Becomes Therapy Dog for Cancer Patient November 27, 2021 Navigating Cancer Survivorship as a Transgender or Non-Binary Person May 5, 2021 Load more HOT NEWS Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... Patient Guide in Hepatocellular Carcinoma Now Available Also in German FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib... A radical project: video game design meets cancer research
